Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $34.2 million.

  • Harvard Bioscience's Non-Current Assets fell 5951.71% to $34.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.7 million, marking a year-over-year decrease of 4470.62%. This contributed to the annual value of $22.2 million for FY2024, which is 979.54% down from last year.
  • Latest data reveals that Harvard Bioscience reported Non-Current Assets of $34.2 million as of Q3 2025, which was down 5951.71% from $35.1 million recorded in Q2 2025.
  • Harvard Bioscience's Non-Current Assets' 5-year high stood at $102.0 million during Q1 2021, with a 5-year trough of $22.2 million in Q4 2024.
  • For the 5-year period, Harvard Bioscience's Non-Current Assets averaged around $70.3 million, with its median value being $85.0 million (2024).
  • Per our database at Business Quant, Harvard Bioscience's Non-Current Assets plummeted by 163.22% in 2022 and then plummeted by 5951.71% in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's Non-Current Assets stood at $37.5 million in 2021, then fell by 19.99% to $30.0 million in 2022, then dropped by 17.98% to $24.6 million in 2023, then decreased by 9.8% to $22.2 million in 2024, then surged by 54.17% to $34.2 million in 2025.
  • Its last three reported values are $34.2 million in Q3 2025, $35.1 million for Q2 2025, and $34.9 million during Q1 2025.